Q-omics provides the consensus-scored ITPK1 profile across patient tissues and cancer cell-line models. ITPK1 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in UCEC. Among the 18 cancer types available for tumor–normal comparison, ITPK1 is differentially expressed in 13, with the highest sampling consensus in HNSC. Additionally, ITPK1 protein abundance shows 35,854 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight UCEC, HNSC, and GBM as cancer lineages where ITPK1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ITPK1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ITPK1 survival associations across molecular data types. ITPK1 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (8) and mass-spec protein abundance (9). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ITPK1 RNA expression–survival associations across cancer types. High ITPK1 expression shows unfavorable associations in ACC, LAML and LUSC, but favorable associations in UCEC, BRCA and LGG. The UCEC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify UCEC as the clearest survival context for ITPK1 RNA expression.
This table summarizes ITPK1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 11. The strongest signals are observed in HNSC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for ITPK1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ITPK1 shows lower tumor expression in LUAD, BLCA and READ and higher tumor expression in HNSC, LIHC and STAD. The HNSC box plot shows higher ITPK1 RNA expression in tumor versus normal tissue (log2 FC = +1.173, t-test p < 0.001).
This table shows molecular features associated with ITPK1 in patient tissues and cancer cell lines. In patient samples, ITPK1 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, ITPK1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in PANCREAS and BLOOD_Lymphoma.
